Want to see IMRX full AI Analyst Report?
IMRX Stock Chart & Stats
$5.56
-$0.24(-10.17%)
At close: 4:00 PM EST
$5.56
-$0.24(-10.17%)
Day’s Range― - ―
52-Week Range$2.90 - $10.08
Previous CloseN/A
Volume3.55M
Average Volume (3M)1.42M
Market Cap
$300.20M
Enterprise Value$187.79
Total Cash (Recent Filing)$156.69M
Total Debt (Recent Filing)$3.73B
Price to Earnings (P/E)―
Beta1.96
Next Earnings
Aug 12, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.17
Shares Outstanding64,697,230
10 Day Avg. Volume982,924
30 Day Avg. Volume1,424,455
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.33
Price to Sales (P/S)0.00
P/FCF Ratio-6.37
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$14.40Price Target Upside158.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.14
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Platform & Discovery EngineImmuneering’s computational biology platform (including AI/ML) is a durable competitive asset that can accelerate target identification and candidate optimization across oncology programs. Over months this reduces per‑asset discovery time and cost, supports pipeline breadth, and can improve hit‑to‑lead productivity versus manual approaches.
De‑risking Via Positive Phase 2a DataUpdated Phase 2a results for atebimetinib show materially better median OS and respectable ORR with manageable safety, and the company plans a pivotal Phase 3 start mid‑2026 with a topline readout mid‑2028. These outcomes structurally de‑risk the lead program and create a clear registrational pathway that can transform future revenue prospects if replicated.
Strengthened Financial LeadershipHiring an experienced biotech CFO with operational and capital markets pedigree strengthens fundraising, budgeting and financial governance. Over the medium term this improves the company’s ability to secure capital for pivotal trials, negotiate partnerships and execute complex financing or collaboration transactions with greater credibility.
Bears Say
No Product RevenueAs a clinical‑stage biotech, Immuneering lacks recurring product revenue and reported effectively zero revenue while incurring large net losses (~$56M in 2025). Structurally this means ongoing operations depend on external financing rather than internal cash generation, increasing dilution and execution risk over the next funding cycles.
Sustained Cash BurnOperating and free cash flow have been consistently negative (operating CF ≈ -$45.3M in 2025) and the TTM pattern remains weak. This persistent burn creates a structural dependence on timely capital raises to fund pivotal trials and pipeline advancement, pressuring management to balance financing cadence against dilution and program timelines.
Limited Balance Sheet Depth & VolatilityWhile low debt reduces insolvency risk, equity has fluctuated materially and returns remain sharply negative, indicating reliance on financing activity to sustain operations. Combined with a small staff and development‑stage profile, the balance sheet offers limited capacity to scale multiple late‑stage programs without partner deals or fresh capital, raising execution and dilution risk.
Immuneering News
IMRX FAQ
What was Immuneering Corp. Class A’s price range in the past 12 months?
Immuneering Corp. Class A lowest stock price was $2.90 and its highest was $10.08 in the past 12 months.
What is Immuneering Corp. Class A’s market cap?
Immuneering Corp. Class A’s market cap is $300.20M.
When is Immuneering Corp. Class A’s upcoming earnings report date?
Immuneering Corp. Class A’s upcoming earnings report date is Aug 12, 2026 which is in 23 days.
How were Immuneering Corp. Class A’s earnings last quarter?
Immuneering Corp. Class A released its earnings results on May 15, 2026. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.252 by $0.042.
Is Immuneering Corp. Class A overvalued?
According to Wall Street analysts Immuneering Corp. Class A’s price is currently Undervalued.
Does Immuneering Corp. Class A pay dividends?
Immuneering Corp. Class A does not currently pay dividends.
What is Immuneering Corp. Class A’s EPS estimate?
Immuneering Corp. Class A’s EPS estimate is -0.27.
How many shares outstanding does Immuneering Corp. Class A have?
Immuneering Corp. Class A has 64,697,230 shares outstanding.
What happened to Immuneering Corp. Class A’s price movement after its last earnings report?
Immuneering Corp. Class A reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.252. Following the earnings report the stock price went up 0.389%.
Which hedge fund is a major shareholder of Immuneering Corp. Class A?
Currently, no hedge funds are holding shares in IMRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immuneering Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.40 (158.99% Upside)
$14.40 (158.99% Upside)
Blogger Sentiment
Bullish
IMRX Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 181.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $36.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 6.0%
Last 30 Days ▼ 6.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
7.90%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
323.84%
Trailing 12-Months
Company Description
Immuneering Corp. Class A
Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations. The second is IMM-6-415, which is being developed to treat solid tumors. Beyond these advanced-stage programs, Immuneering's early-stage pipeline includes five oncology initiatives aimed at components of the MAPK or mTOR signaling pathways, along with two neuroscience programs, all currently in the discovery phase. Founded in 2008, Immuneering Corporation is headquartered in Cambridge, Massachusetts. It was formerly a subsidiary of Teva Pharmaceutical Industries Limited.
IMRX Stock 12 Month Forecast
Average Price Target
$14.40
▲(158.99% Upside)
Technical Analysis
Ownership Overview
9.38% Insiders
15.57% Mutual Funds
0.40% Other Institutional Investors
66.65% Public Companies and
Individual Investors